The U.S. Food and Drug Administration has moved to ease restrictions on CAR-T cell therapies by removing the Risk Evaluation and Mitigation Strategies (REMS) requirements. This regulatory shift reflects accumulated clinical experience with managing adverse events such as cytokine release syndrome (CRS) and neurological toxicities, thereby broadening patient access. The change affects therapies from major firms including Bristol Myers Squibb, Gilead Sciences, Johnson & Johnson, and Novartis. The agency considers healthcare providers sufficiently versed in treating side effects, enabling safe administration without previous oversight measures.